Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors

BACKGROUND: The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yu‐Qian, Xu, Lan‐Ping, Liu, Kai‐Yan, Zhang, Xiao‐Hui, Yan, Chen‐Hua, Jin, Jian, Huang, Xiao‐Jun, Wang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045915/
https://www.ncbi.nlm.nih.gov/pubmed/33566460
http://dx.doi.org/10.1002/cac2.12140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045915/
https://www.ncbi.nlm.nih.gov/pubmed/33566460
http://dx.doi.org/10.1002/cac2.12140

Ejemplares similares